AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28040235 — intervention group
Group type: EXPERIMENTAL
Intervention: lidocaine 20mg
Number of subjects: 120
Study 28040235 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 120
Study 25898203 — intervention group
Group type: EXPERIMENTAL
Intervention: Problems on four domains (functional, somatic, mental, social)
Number of subjects: 2681
Study 25898203 — intervention group
Group type: EXPERIMENTAL
Intervention: Problems on all four domains
Number of subjects: 2681
Study 25898203 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased number of domains with problems
Number of subjects: 2681
Study 23689430 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance vandetanib (300 mg/day orally)
Number of subjects: 162
Study 23689430 — intervention group
Group type: COMPARATOR
Intervention: Maintenance placebo
Number of subjects: 162
Study 20467870 — intervention group
Group type: EXPERIMENTAL
Intervention: ePTFE/FEP-covered stents
Number of subjects: 80
Study 20467870 — intervention group
Group type: COMPARATOR
Intervention: Bare nitinol stents
Number of subjects: 80
Study 19786221 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical clindamycin
Number of subjects: 82
Study 19786221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 15969905 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming of visual search by repeated target location
Number of subjects: 2
Study 15969905 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming of visual search by repeated target color
Number of subjects: 2
Study 15969905 — intervention group
Group type: EXPERIMENTAL
Intervention: Briefer displays
Number of subjects: 2
Study 15969905 — intervention group
Group type: EXPERIMENTAL
Intervention: Color priming from missed targets
Number of subjects: 2
Study 10573550 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin A, 15 mg retinol equivalent (RE) with TOPV
Number of subjects: 467
Study 10573550 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin A, 7.5 mg RE with TOPV
Number of subjects: 467
Study 10573550 — intervention group
Group type: COMPARATOR
Intervention: Placebo with TOPV
Number of subjects: 467
Study 9199118 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic exposure to carbon disulfide (CS2)
Number of subjects: 140
Study 1672698 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (ATN) 100 mg
Number of subjects: 3
Study 1672698 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (PRP) 40 mg
Number of subjects: 3
Study 1672698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 7154707 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly bolus (5 mg/m2 i.v. X 4)
Number of subjects: 46
Study 7154707 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated daily injections (0.5 mg/m2 i.v. q.12 h X 10, course to be repeated after 10‐15 days)
Number of subjects: 46
Study 31859205 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge education intervention
Number of subjects: 66
Study 31859205 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 66
Study 31383594 — intervention group
Group type: EXPERIMENTAL
Intervention: active cTBS
Number of subjects: 30
Study 31383594 — intervention group
Group type: COMPARATOR
Intervention: sham cTBS
Number of subjects: 30
Study 29489429 — intervention group
Group type: EXPERIMENTAL
Intervention: Nut consumption (two or more servings of nuts per week)
Number of subjects: 826
Study 29489429 — intervention group
Group type: EXPERIMENTAL
Intervention: Tree nut intake
Number of subjects: 826
Study 26833162 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir (LPV)
Number of subjects: 20
Study 26833162 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir (RTV)
Number of subjects: 20
Study 26833162 — intervention group
Group type: EXPERIMENTAL
Intervention: Gag amino acid substitutions
Number of subjects: 20
Study 26833162 — intervention group
Group type: EXPERIMENTAL
Intervention: Gag and protease amino acid changes
Number of subjects: 20
Study 25174321 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized asthma management system (workflow-integrated, computer-based asthma scoring, guideline-compliant order sets)
Number of subjects: 788
Study 25174321 — intervention group
Group type: COMPARATOR
Intervention: Standard asthma management
Number of subjects: 788
Study 25174321 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized asthma management system
Number of subjects: 788
Study 21934629 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan (240 mg) with Hydrochlorothiazide (HCTZ, 25 mg)
Number of subjects: 32
Study 21934629 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ, 25 mg) with Fimasartan (240 mg)
Number of subjects: 32
Study 21934629 — intervention group
Group type: COMPARATOR
Intervention: Fimasartan alone
Number of subjects: 32
Study 18981951 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g of soy protein with 160 mg of total isoflavones (64 mg genistein, 63 mg daidzein, and 34 mg glycitein) for 12 weeks
Number of subjects: 75
Study 18981951 — intervention group
Group type: COMPARATOR
Intervention: 20 g of soy protein placebo for 12 weeks
Number of subjects: 75
Study 18981951 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of pre‐post change between the groups
Number of subjects: 75
Study 17244766 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (200 mg once daily for 5 days)
Number of subjects: 12
Study 17244766 — intervention group
Group type: COMPARATOR
Intervention: Rosiglitazone (4 mg single dose)
Number of subjects: 12
Study 15684445 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam
Number of subjects: 39
Study 15684445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 12428688 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 600 microg four times a day (QID)
Number of subjects: 6
Study 12428688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 12428688 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 6
Study 9537487 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed injection of DTaP and candidate Hib vaccine
Number of subjects: 822
Study 9537487 — intervention group
Group type: EXPERIMENTAL
Intervention: Separate injection of DTaP and commercial Hib vaccine
Number of subjects: 822
Study 9537487 — intervention group
Group type: EXPERIMENTAL
Intervention: Separate injection of DTaP and candidate Hib vaccine
Number of subjects: 822
Study 9537487 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster doses (separate or mixed injections of Hib and DTaP vaccines)
Number of subjects: 822
Study 9537487 — intervention group
Group type: COMPARATOR
Intervention: Mixed DTaP and Hib vaccines
Number of subjects: 822
Study 7702021 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resistant starch (RS) diet (59.1 +/‐ 4.7 g RS)
Number of subjects: 8
Study 7702021 — intervention group
Group type: COMPARATOR
Intervention: Low-resistant starch (RS) diet (5.2 +/‐ 0.4 g RS)
Number of subjects: 8
Study 7702021 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resistant starch (RS) diet
Number of subjects: 8
Study 30142047 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated lab instruction (E‐to‐S)
Number of subjects: 515
Study 30142047 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard lab instruction (S‐to‐E)
Number of subjects: 515
Study 30142047 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard lab instruction only)
Number of subjects: 515
Study 28891423 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg every 2 weeks)
Number of subjects: 906
Study 28891423 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab (10 mg/kg every 3 weeks for four doses, then every 12 weeks)
Number of subjects: 906
Study 28891423 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 906
Study 28891423 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab
Number of subjects: 906
Study 25919526 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrievable inferior vena cava filter plus anticoagulation
Number of subjects: 399
Study 25919526 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulation alone
Number of subjects: 399
Study 23178794 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid treatment
Number of subjects: 30
Study 23178794 — intervention group
Group type: COMPARATOR
Intervention: Untreated NP
Number of subjects: 30
Study 21530948 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted surgery
Number of subjects: 56
Study 21530948 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic surgery
Number of subjects: 56
Study 19433702 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention by ward-based pharmacists
Number of subjects: 400
Study 19433702 — intervention group
Group type: COMPARATOR
Intervention: Standard care without pharmacist involvement
Number of subjects: 400
Study 17709073 — intervention group
Group type: EXPERIMENTAL
Intervention: EDTA
Number of subjects: 60
Study 17709073 — intervention group
Group type: EXPERIMENTAL
Intervention: EDTA + NaOCl
Number of subjects: 60
Study 17709073 — intervention group
Group type: EXPERIMENTAL
Intervention: EDTAC
Number of subjects: 60
Study 17709073 — intervention group
Group type: EXPERIMENTAL
Intervention: EDTAC + NaOCl
Number of subjects: 60
Study 17709073 — intervention group
Group type: EXPERIMENTAL
Intervention: EGTA
Number of subjects: 60
Study 17709073 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline-HCl
Number of subjects: 60
Study 17709073 — intervention group
Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 60
Study 15017192 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer model for predicting stone passage and duration
Number of subjects: 301
Study 15017192 — intervention group
Group type: COMPARATOR
Intervention: Experienced urologists
Number of subjects: 301
Study 15017192 — intervention group
Group type: COMPARATOR
Intervention: Urology residents
Number of subjects: 301
Study 15017192 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer model tested at a private hospital
Number of subjects: 301
Study 11696113 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid nutrient test meal (1350 kJ)
Number of subjects: 28
Study 11696113 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed liquid/solid nutrient test meal (1350 kJ)
Number of subjects: 28
Study 11696113 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed viscous/solid nutrient test meal (1350 kJ)
Number of subjects: 28
Study 9950098 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human interferon alpha 2a (rIFN alpha) at 1.0 IU/lb
Number of subjects: 177
Study 9950098 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human interferon alpha 2a (rIFN alpha) at 1.0 IU/lb and 10.0 IU/lb
Number of subjects: 177
Study 9950098 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 177
Study 7799590 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for bile duct fistula
Number of subjects: 208
Study 3259889 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of propofol supplemented with nitrous oxide in oxygen (group I)
Number of subjects: 60
Study 3259889 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane and nitrous oxide in oxygen (group II)
Number of subjects: 60
Study 3259889 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of propofol with repeated bolus doses of alfentanil (group III)
Number of subjects: 60
Study 4469858 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein diet
Number of subjects: 5
Study 4469858 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat diet
Number of subjects: 5
Study 4469858 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate diet
Number of subjects: 5
Study 4469858 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard diet
Number of subjects: 5
Study 29914389 — intervention group
Group type: EXPERIMENTAL
Intervention: QoL‐AD (13 Items)
Number of subjects: 73
Study 29914389 — intervention group
Group type: EXPERIMENTAL
Intervention: QoL‐AD NH (15 Items)
Number of subjects: 73
Study 28716357 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000mg omega-3 fatty acids from flaxseed oil supplements, twice a day for 12 weeks
Number of subjects: 60
Study 25438720 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoinjector
Number of subjects: 156
Study 25438720 — intervention group
Group type: COMPARATOR
Intervention: Needle and syringe
Number of subjects: 156
Study 24187866 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 120
Study 24187866 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear acupuncture
Number of subjects: 120
Study 24187866 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 21951567 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment
Number of subjects: 0
Study 21951567 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 0
Study 18504324 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased creatinine
Number of subjects: 10881
Study 18504324 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased GFR from Cockroft and Gault
Number of subjects: 10881
Study 18504324 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased GFR from Modification of Diet in Renal Disease study group
Number of subjects: 10881
Study 18504324 — intervention group
Group type: EXPERIMENTAL
Intervention: Microalbuminuria
Number of subjects: 10881
Study 18504324 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction between microalbuminuria and GFR from Cockroft and Gault
Number of subjects: 10881
Study 16607544 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioiodine therapy without carbimazole
Number of subjects: 227
Study 14679407 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol adjustable dosing
Number of subjects: 995
Study 14679407 — intervention group
Group type: COMPARATOR
Intervention: Budesonide/formoterol fixed dosing
Number of subjects: 995
Study 11006427 — intervention group
Group type: COMPARATOR
Intervention: Intervention (training to recognize metabolic hunger)
Number of subjects: 209
Study 9206240 — intervention group
Group type: EXPERIMENTAL
Intervention: Hehuantang (HT)
Number of subjects: 59
Study 9206240 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - Nifedipine tablet
Number of subjects: 59
Study 1594977 — intervention group
Group type: EXPERIMENTAL
Intervention: Sheehan Disability Scale
Number of subjects: 0
Study 6692650 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 h fast
Number of subjects: 9
Study 6692650 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 h fast
Number of subjects: 9
Study 6692650 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body subatmospheric pressure after 48 h fast
Number of subjects: 9
Study 6692650 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing after 48 h fast
Number of subjects: 9
Study 31296133 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐3D
Number of subjects: 15
Study 31296133 — intervention group
Group type: EXPERIMENTAL
Intervention: GF‐3D
Number of subjects: 15
Study 31296133 — intervention group
Group type: COMPARATOR
Intervention: HD‐2D
Number of subjects: 15
Study 29847190 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (five group sessions about hookah smoking withdrawal)
Number of subjects: 140
Study 29847190 — intervention group
Group type: COMPARATOR
Intervention: Conventional recommendations for quitting hookah (control group)
Number of subjects: 140
Study 26890759 — intervention group
Group type: EXPERIMENTAL
Intervention: LC-n3-FA (2,200 mg/day, n=22)
Number of subjects: 44
Study 26890759 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=22)
Number of subjects: 44
Study 25442725 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg acetaminophen/10 mg hydrocodone
Number of subjects: 100
Study 25442725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 22318394 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimeric‐001 vaccine (250 μg with adjuvant)
Number of subjects: 60
Study 22318394 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimeric‐001 vaccine (500 μg with adjuvant)
Number of subjects: 60
Study 22318394 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimeric‐001 vaccine (250 μg without adjuvant)
Number of subjects: 60
Study 22318394 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimeric‐001 vaccine (500 μg without adjuvant)
Number of subjects: 60
Study 22318394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 21265202 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential electrical stimulation (IES)
Number of subjects: 166
Study 21265202 — intervention group
Group type: COMPARATOR
Intervention: Drug treatment (Control)
Number of subjects: 166
Study 17492298 — intervention group
Group type: EXPERIMENTAL
Intervention: New technique for sacrospinous ligament fixation
Number of subjects: 57
Study 17492298 — intervention group
Group type: COMPARATOR
Intervention: Deschamps ligature carrier
Number of subjects: 57
Study 14985677 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochanin (40 mg/day)
Number of subjects: 80
Study 14985677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 14985677 — intervention group
Group type: COMPARATOR
Intervention: Biochanin vs Placebo
Number of subjects: 80
Study 14985677 — intervention group
Group type: EXPERIMENTAL
Intervention: Formononetin
Number of subjects: 80
Study 14985677 — intervention group
Group type: COMPARATOR
Intervention: Placebo for Formononetin
Number of subjects: 80
Study 11824703 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading the piece of fiction
Number of subjects: 85
Study 11824703 — intervention group
Group type: COMPARATOR
Intervention: Listening to the piece of fiction
Number of subjects: 85
Study 11824703 — intervention group
Group type: COMPARATOR
Intervention: Watching the piece of fiction
Number of subjects: 85
Study 9715673 — intervention group
Group type: EXPERIMENTAL
Intervention: NFPA 1500 (1987) standard configuration
Number of subjects: 10
Study 9715673 — intervention group
Group type: COMPARATOR
Intervention: Hip-boot configuration
Number of subjects: 10
Study 7519977 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 12 mg/day
Number of subjects: 6
Study 7519977 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (2 mg/day and 6 mg/day)
Number of subjects: 6
Study 7519977 — intervention group
Group type: COMPARATOR
Intervention: Placebo buprenorphine
Number of subjects: 6
Study 2500941 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of insulin in class B-F diabetic patients
Number of subjects: 112
Study 2500941 — intervention group
Group type: COMPARATOR
Intervention: Diet
Number of subjects: 112
Study 2500941 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids administration to the mother
Number of subjects: 112
Study 2500941 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphatidylglycerol determination in amniotic fluid
Number of subjects: 112
Study 31648515 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided transversus abdominis plane (TAP) block using 0.25% bupivacaine solution (0.5 ml kg−1)
Number of subjects: 94
Study 31648515 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided quadratus lumborum (QL) block using 0.25% bupivacaine solution (0.5 ml kg−1)
Number of subjects: 94
Study 31648515 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal epidural block using 0.25% bupivacaine solution (0.5 ml kg−1)
Number of subjects: 94
Study 29155036 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based self-acupressure
Number of subjects: 221
Study 29155036 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 221
Study 27439031 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (4 or 5 mg daily for 16 weeks)
Number of subjects: 64
Study 27439031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 24580721 — intervention group
Group type: EXPERIMENTAL
Intervention: Headstrong CD-ROM program
Number of subjects: 35
Study 24580721 — intervention group
Group type: COMPARATOR
Intervention: Educational control CD-ROM program
Number of subjects: 35
Study 22735866 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol IV 5‐15 mg or up to HR ≤ 60 bpm (M)
Number of subjects: 50
Study 22735866 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem IV 0.25 to 0.60 mg/kg or up to HR ≤ 60 bpm (D)
Number of subjects: 50
Study 22735866 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 50
Study 19687327 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine-based chemotherapy
Number of subjects: 55
Study 19687327 — intervention group
Group type: COMPARATOR
Intervention: Proteolytic enzyme therapy
Number of subjects: 55
Study 17653691 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronised fenofibrate (200 mg/day)
Number of subjects: 171
Study 15774493 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting heart rate > or =83 bpm
Number of subjects: 24913
Study 15774493 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting heart rate between 77-82 bpm
Number of subjects: 24913
Study 15774493 — intervention group
Group type: COMPARATOR
Intervention: Resting heart rate < or =62 bpm
Number of subjects: 24913
Study 12474116 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandospirone (60 mg)
Number of subjects: 7
Study 12474116 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandospirone (30 mg or 60 mg)
Number of subjects: 7
Study 12474116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 10405985 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate aerobic exercise training (EXC)
Number of subjects: 29
Study 10405985 — intervention group
Group type: COMPARATOR
Intervention: Flexibility/toning control (FT-CON)
Number of subjects: 29
Study 7588663 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg kg‐1
Number of subjects: 38
Study 7588663 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone 4.0 mg kg‐1
Number of subjects: 38
Study 2123904 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic agent (100 mg of recombinant tissue‐type plasminogen activator given over 3 h)
Number of subjects: 91
Study 2123904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91